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Prognostic Significance of b-Human Chorionic
Gonadotropin and PAX8 Expression
in Anaplastic Thyroid Carcinoma
Nils Becker,1 Rebecca D. Chernock,1,2 Brian Nussenbaum,2 and James S. Lewis Jr.1,2
Background: Anaplastic thyroid carcinoma (ATC) is a rare, aggressive malignancy with a median survival of five
months. Multimodality treatment is associated with some improvement in survival, but patients are only in-
frequently curable. Although b-hCG secretion has been reported in many neoplasms, it has never been described
in ATC. The objectives of this study were to report a case of b-hCG–secreting ATC and to study the expression
and significance of b-hCG and PAX8 in an institutional cohort of ATC.
Methods: The sentinel case was characterized and then immunohistochemistry was performed for b-hCG and
PAX8 on 30 ATC patients. Clinical follow-up was obtained by chart review.
Results: The sentinel patient with b-hCG–secreting ATC had a dramatic response to chemotherapy and radiation.
After surgical excision of residual disease, the patient developed a regional recurrence of differentiated thyroid
carcinoma at 18 months. However, she is now, 30 months after initial therapy, with no evidence of disease and no
detectable serum b-hCG or thyroglobulin. Five of the 30 (17%) total ATCs were positive for b-hCG and 18 (60%) for
PAX8. Outcomes for the b-hCG–positive cases were not significantly different from those for negative ones.
However, none of the other four b-hCG–positive ATC patients received treatment with either chemotherapy or
radiation. Interestingly, PAX8 positivity correlated with statistically significantly better overall survival ( p= 0.019).
Conclusions: b-hCG is expressed in a minority of ATCs. Although only a single case in the study had diffuse
immunohistochemical expression, the response it showed to aggressive multimodality therapy and the resulting
favorable outcome suggest that b-hCG–positive ATC may be a unique tumor subtype, or possibly even a unique
entity. PAX8 is a useful marker of ATC and may be helpful in the differential diagnosis with other malignant
neoplasms.
Introduction
Anaplastic (or undifferentiated) thyroid carcinoma(ATC) is a rare malignancy that is clinically one of the
most aggressive in all of oncology. It is defined by the World
HealthOrganization as a ‘‘malignant tumor that histologically
appears wholly or partially composed of undifferentiated
cells that exhibit immunohistochemical or ultrastructural
features indicative of epithelial differentiation’’ (1). Although
this definition suggests that immunohistochemistry or elec-
tron microscopy is requisite, in routine practice, many ATCs
are diagnosed just based on the finding of a pleomorphic,
spindled, or epithelioid carcinoma without specific histologic
differentiation. A significant minority of ATCs have a well-
differentiated carcinoma component, either follicular or pap-
illary (2–4). There are reports of ATCs arising from a pre-
existing Hu¨rthle cell carcinoma, and although it has been
proposed that Hu¨rthle cell carcinomas with foci of ATC tend
to have a worse outcome than other Hu¨rthle cell carcinomas
(5), no definitive conclusion can bemade. It is not clear, then, if
ATCs arising fromHu¨rthle cell carcinomas constitute a subset
with a different outcome compared to other ATCs. The well-
differentiated component may be intermixed histologically
with the ATC at primary presentation or it may have been
previously diagnosed and treated months or years before the
actual development of the ATC. For the subset of cases that
are difficult to recognize histologically as carcinoma, such as
when they are composed almost entirely of spindled or
markedly pleomorphic giant cells, immunohistochemistry for
epithelial markers such as cytokeratin becomes necessary (4).
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The clinical presentation is typically a rapidly growing,
markedly infiltrative neck mass with hoarseness, dysphagia,
vocal cord paralysis, pain, and/or dyspnea. The median
survival is usually less than six months after diagnosis (4,6).
Multimodality treatmentwith surgery (for resectable disease),
radiation, and chemotherapy is associated with improved
survival, but patients are only very infrequently curable (6–9).
Recently, we identified what we believe is the first case of a
b-hCG–secreting ATC. The patient’s serum b-hCG was
elevated at diagnosis, and the tumor responded dramatically
to chemotherapy and radiation. It regressed extensively and
was subsequently surgically resectable. The patient is alive
and disease-free over two years after initial therapy.
Although b-hCG secretion has been reported in many
neoplasms, particularly carcinomas (10–16), including being
detectable in the serum in a minority of them, it has not been
described in ATC. In addition, PAX8, an immunohistochem-
ical marker of renal, ovarian, and thyroid carcinomas (17–19),
has been described as a potentially useful (as well as quite
sensitive) marker for ATC (19,20). It has been shown to be
consistently detectable by immunohistochemistry in the ma-
jority of differentiated thyroid carcinomas, but it has not been
extensively studied in ATC. Its expression has not been cor-
related with patient outcomes.
The aims of this study were to report the index case with a
b-hCG–secreting ATC, and, given its apparently unique
clinical features, to determine the frequency of b-hCG ex-
pression in a larger cohort of ATC. Further, we sought to
characterize the clinical and pathologic features of the positive
tumors and to investigate if the expression of PAX8 was re-
lated to these cases or to patient prognosis.
Materials and Methods
After characterization of the sentinel b-hCG–secreting ATC
case, with Human Research Protection Office approval, an
additional 29 cases of ATC were retrieved from Barnes Jewish
Hospital and Washington University pathology department
files. Cases were identified by a pathology database keyword
search using the terms ‘‘thyroid’’ and ‘‘anaplastic carcinoma’’ or
‘‘undifferentiated carcinoma.’’ Cases were included if they
fulfilled the following criteria, derived from the World Health
Organization definition (1): (i) the majority of the tumor had to
be undifferentiated or anaplastic; (ii) there was convincing
evidence of epithelial differentiation histologically or, if not,
then confirmation of such by either pancytokeratin, thyro-
globulin, or thyroid transcription factor 1 immunohistochem-
istry. The ATCs were subtyped into the following (1): (i)
squamoid, (ii) spindled, (iii) pleomorphic, (iv) carcinosarcoma
with cartilage or bone formation or other histologically defined
sarcoma differentiation, (v) paucicellular, (vi) lymphoepithe-
lioma-like, and (vii) giant cell (3). More than one subtype was
allowable in an individual tumor. The presence of a coexisting
differentiated carcinoma component was assessed by routine
histologic examination or, in biopsy only cases, by clinical
history of prior differentiated carcinoma, with tumors defined
by traditional World Health Organization definitions. Clinical
follow-up information was obtained by chart review.
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed,
paraffin-embedded4lmtissuesectionsonaVentanaBenchmark
LT automated immunostainer (Ventana Medical Systems,
Inc., Tucson, AZ) for PAX8 (Proteintech Group, Inc., Chicago,
IL; product # 10336-1AP; rabbit polyclonal; dilution 1:80; in-
cubation 40minutes at 37C) and for b-hCG (VentanaMedical
Systems, Inc.; product # 760-2650; rabbit polyclonal; pre-
diluted; incubation 16 minutes at 37C). Both immunostains
utilized the standard Ventana CC1 mild solution (1mM
EDTA buffer at pH 8.0) for antigen retrieval. For PAX8, a
case of renal cell carcinoma, clear cell type, served as the
positive control and a slide that was not incubated with
primary antibody as the negative control. For b-hCG, normal
placenta was used as the positive control, and then a slide
that was not incubated with primary antibody as the nega-
tive control. The immunostained slides were reviewed by
three study pathologists (N.B., R.D.C., J.S.L.), and staining in
both the ATC and the differentiated carcinoma component
(when present) was characterized. Staining intensity for
b-hCG was categorized as weak, moderate, or strong. In
addition, the staining distribution was categorized in quar-
tiles as follows: 0, negative; 1 + , 1–25% of tumor cells posi-
tive; 2 + , > 25–50%; 3 + , > 50–75%; 4 + , > 75%. PAX8 staining
was characterized as positive or negative without further
stratification based on the presence of any definitive tumor
cell nuclear staining. Discrepancies were resolved by con-
sensus review.
Statistics
Statistical analysis was performed using GraphPad Prism 6
(GraphPad Software, Inc., La Jolla, CA). Associations between
the categorical clinical and pathological features were as-
sessed using two-tailed Fisher’s exact tests. Age, as a contin-
uous variable, was simply divided at the median into two
separate groups for analysis. Overall survival was defined as
the time between the initial surgical pathology diagnosis to
the date of death. Survival curves were determined by the
Kaplan–Meier method and statistically analyzed using the
Gehan–Breslow–Wilcoxon method.
Results
b-hCG–positive sentinel patient
The patient is a 54-year-old woman who presented to an
outside hospital in 2010 with a rapidly enlarging neck mass,
which on examination and imaging was arising from the
left thyroid lobe. Preoperatively, a serum b-hCG level was
drawn in order to rule out pregnancy. When it returned as
elevated, the outside surgeon declined to operate because of
concern for possible pregnancy. She sought further treat-
ment at Washington University in St. Louis. At presenta-
tion, she had mild neck pain but had no dysphagia,
dyspnea, or hoarseness. Further sonographic and computer
tomographic imaging showed a large, heterogeneously
enhancing, unresectable left thyroid mass measuring ap-
proximately 6.2 cm · 4.8 cm · 4.5 cm (Fig. 1). The mass re-
placed almost the entire left thyroid lobe. Although the
airway was deviated to the right, there was no overt tra-
cheal invasion. Additional hypoechoic, subcentimeter
nodules were seen in the right thyroid lobe. Left cervical
lymphadenopathy was also present with the largest lymph
node seen lateral to the internal jugular vein in the mid neck
measuring 1.6 cm. Serum b-hCG was 48.0 IU/L (normal
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< 5 IU/L) and serum calcitonin was < 5 pg/mL (within
normal limits). She was postmenopausal and an examina-
tion by her obstetrician revealed no evidence for pregnancy.
Fine-needle aspiration of the left thyroid mass was positive
for a high-grade malignancy consistent with ATC. A subse-
quent needle core biopsy showed a high-grade malignant
neoplasm composed of sheets of pleomorphic cells with in-
tervening hyalinized stroma (Fig. 2). The tumor cells were
poorly cohesive and showed epithelioid to spindled features.
Nuclei were angulated and hyperchromatic, and there were
scattered prominent nucleoli. There was brisk mitotic activity
and extensive necrosis. A panel of immunohistochemical
stains performed at the time of diagnosis showed the tumor
cells to be strongly and diffusely positive for pancytokeratin,
vimentin, and b-hCG (Fig. 2). The tumor cells were negative
for CD45, placental alkaline phosphatase, Oct3/4, inhibin,
calcitonin, CD31, and thyroid transcription factor 1. The di-
agnosis of ATCwas rendered after choriocarcinomawas ruled
out by the lack of any multinucleated cell (syncytiotropho-
blastic) component and also by the lack of inhibin or placental
alkaline phosphatase expression.
The patient received intensity-modulated radiation therapy
to 61.2 G in twice daily fractions and taxol chemotherapy of
40mg/m2weekly for 5weeks. After a dramatic clinical response
with the tumor decreasing in size by more than one-third and
going from fixed to mobile, the tumor became surgically resect-
able. The serum b-hCG level remained elevated, concerning for
persistent viable disease. Resection of the entire thyroid gland
and left neck regional lymph nodes showed a 4.7 cm·3.8 cm·
3.5 cm extensively necrotic tumor in the left lobe (Fig. 3A). Less
than 25% of the tumor was still viable, and it consisted of a
pleomorphic, spindled, and epithelioid neoplasm with large
nuclei with vesicular chromatin and prominent nucleoli. Occa-
sional mitotic figures were seen. The tumor was present in ill-
defined sheets, and, interestingly, did not show an infiltrative
growth pattern, having a relatively defined periphery with a
pseudocapsule (Fig. 3B). The margins of resection were negative
for tumor. Immunohistochemistry was performed and showed
the tumor cells to be strongly and diffusely positive for cytoker-
atin 7 and b-hCG but negative for S100. A component of
well-differentiated carcinoma with large cells with abundant,
eosinophilic cytoplasm and round nuclei with prominent nucle-
oli was also present, features of Hu¨rthle cell carcinoma (Fig. 3C).
The left neck lymph node dissection showed metastatic Hu¨rthle
cell carcinoma in 1 of 32 lymph nodes, but no metastatic ATC.
A postoperative b-hCG level was < 5 IU/L. The patient re-
coveredwell after surgery and then, based on pathology results,
received 100 mCi of radioactive iodine with the post-treatment
scan showing expected thyroid bed uptake only. She remained
well and disease-free until 18 months postsurgery, when she
developed a positive thyroglobulin level of 7ng/mL with a
withdrawal TSH level of 36mU/L. A 5 mCi iodine scan using
131I during hormonal withdrawal revealed no uptake, but a
subsequent fluorodeoxyglucose positron emission tomogra-
phy/computed tomography scan showed a left paratracheal
mass.Her b-hCG level continued to be <5 IU/L, however. Fine-
needle aspiration showed a pleomorphic carcinoma,whichwas
favored to be recurrent ATC. Subsequent surgical resection of
the mass showed two 0.4 cm foci of Hu¨rthle cell carcinoma in
follicles and with extensive fibrosis and cystic change. The nu-
clei were vesicular with prominent nucleoli but no significant
mitotic activity. The nuclear atypia was felt to be treatment
related. There was no evidence of ATC, and the resection
marginswere tumor-free. She is nowalive anddisease-free at 30
months after her initial diagnosis. The quantitative serum
b-hCG level continues to be undetectable.
Clinicopathologic features of the tumor cohort
Clinicopathologic features of the cases are presented in
Table 1. The cases consisted of the following types: squamoid
(15/30 [50%]), spindled (16/30 [53%]), pleomorphic (10/30
[33%]), lymphoepithelioma-like (1/30 [3%]), and giant cell
(7/30 [23%]). There were no carcinosarcoma or paucicel-
lular types. There was a coexisting differentiated carcinoma
FIG. 1. Pretreatment (A) and post-treatment (B) computed
tomography scans for the index b-hCG–positive anaplastic
carcinoma patient showing a large, relatively circumscribed
and heterogeneous mass in the left thyroid lobe (indicated by
‘‘T’’). There is marked deviation of the trachea to the right
(indicated by arrow) and also associated right neck lymph-
adenopathy (indicated by ‘‘N’’). In the post-treatment scan, the
tumor is small, more cystic, and with degenerative features.
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component in 19 of the 30 cases (63%). These were as follows:
papillary carcinoma (13/30 [43%]), insular carcinoma (2/30
[7%]), follicular carcinoma (1/30 [3%]), Hu¨rthle cell carcinoma
(1/30 [3%]), and unknown/not otherwise specified (2/30
[7%]).
Immunohistochemistry
Immunohistochemistry results are presented in Tables 1
and 2. b-hCG expression was present in 5 of 30 cases (17%),
but only the sentinel case showed strong, diffuse staining. The
FIG. 3. Gross and histologic features of the index b-hCG–positive anaplastic thyroid carcinoma on surgical resection. (A)
Gross photograph of the left thyroid lobe showing a circumscribed, heterogeneous, yellow-tan, necrotic tumor mass replacing
most of the lobe. (B) Low-power view of the tumor showing the necrotic anaplastic (upper right) and Hu¨rthle cell carcinoma
(lower left) components (100 · ). (C) High-power view of the anaplastic component showing pleomorphic, spindled to epi-
thelioid tumor cells with prominent nucleoli in a hyalinized stroma (400 · ). (D) High-power view of the Hu¨rthle cell
carcinoma component showing polygonal cells in follicles with central colloid and with abundant, eosinophilic cytoplasm
and round nuclei with prominent nucleoli (400 · ). (E) Immunohistochemistry for b-hCG showing the anaplastic component
to be strongly and diffusely positive (200 · ). (F) Immunohistochemistry for b-hCG showing the Hu¨rthle cell component to be
negative (200 · ). Color images available online at www.liebertpub.com/thy
FIG. 2. Histologic features of the index b-hCG–positive anaplastic thyroid carcinoma on needle biopsy. (A) Low-power
view showing scant needle core fragments consisting entirely of tumor and hyalinized peritumoral stroma (40· ). (B) High-
power view showing large, pleomorphic tumor cells with moderate amounts of amphophilic cytoplasm and pleomorphic,
somewhat angulated nuclei, many with prominent nucleoli (400 · ). (C) b-hCG immunohistochemistry showing the tumor to
be strongly and diffusely positive (40· ). Color images available online at www.liebertpub.com/thy
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remaining positive cases showed either strong b-hCG staining
in less than 25% of cells, or just moderate intensity staining in
up to 75% of the cells (Fig. 4). No expression was detected in
any of the differentiated thyroid components. b-hCG ex-
pression was not significantly associated with any of the
other clinical or pathologic variables. PAX8 staining was
present in the ATC component of 18 of 30 (60%) cases, in-
cluding 2 of the 5 (40%) b-hCG–positive cases. The differ-
entiated componentwas positive for PAX8 in all 14 cases that
had one. The index case, with strong and diffuse b-hCG ex-
pression and positive serum b-hCG, was negative for PAX8.
There was no correlation between b-hCG and PAX8 ex-
pression ( p = 0.36). PAX8-positive patients were statistically
significantly younger than the PAX8-negative patients
(61.8 – 9.8 vs. 71.3 – 9.0 years, p = 0.01) and more likely to
have undergone surgical treatment ( p = 0.018).
Survival analysis
Twenty-seven of the 29 (93%) patients with clinical data
available died during the follow-up period, at a median of 3.3
months, and all with progressive disease. Follow-up of the
five b-hCG–positive patients showed that only the index case
patient survived. However, the remaining four patients did
not receive multimodality therapy. Three of four underwent
surgical resection but none were treated with chemotherapy
or radiation therapy. These four patients all died at a median
of 2.7 months (82 days). The median survival of the b-hCG–
positive cases (106 days) was comparable to the b-hCG–
negative ones (110 days) and there was no difference in uni-
variate survival analysis by b-hCG expression ( p = 0.63)
(Fig. 5). Interestingly, PAX8-positive patients had improved
overall survival (median 4.9 months vs. 2.0 months, p= 0.019).
Among the major clinical and pathologic features (Fig. 5),
patients who received surgical treatment had statistically
significantly improved overall survival ( p= 0.0073), and there
was a trend toward improved survival by patient age
( p = 0.12), but this was not statistically significant.
Discussion
ATC is one of the most aggressive human cancer types.
Although some treatments have shown improvement in
survival, the studies are retrospective and generally consist of
small numbers of patients. Surgical resection, if feasible, does
appear to be associated with improved survival (8,21).
Table 1. Clinicopathologic Features of the Patient Cohort
All
(n = 30)
b-hCG–positive
(n = 5)
b-hCG-negative
(n = 25) pa
PAX8-positive
(n = 18)
PAX8–negative
(n = 12) pb
Age (mean – SD) 65.6 – 10.4 66.8 – 10.3 65.4 – 10.7 0.78 61.8 – 9.8 71.3 – 9.0 0.01
Sex, n (%) 0.16 0.72
Male 16 (53.3) 1 (20) 15 (60) 9 (50) 7 (58.3)
Female 14 (46.7) 4 (80) 10 (40) 9 (50) 5 (41.7)
Median survival (days) 106 106 110 0.71 146 59.5 0.04
T stage, n (%) 1.0 0.56
T4A 4 (17.4) 1 (25) 3 (15.8) 2 (12.5) 2 (28.6)
T4B 19 (82.6) 3 (75) 16 (84.2) 14 (87.5) 5 (71.4)
T4X 7 1 6 2 5
N stage, n (%) 0.26 0.26
N0 2 (13.3) 1 (50) 1 (7.7) 1 (7.7) 1 (50)
N+ 13 (86.7) 1 (50) 12 (92.3) 12 (92.3) 1 (50)
NX 15 3 12 5 10
Margin status, n (%) 1.0 0.59
Negative 4 (17.4) 1 (25) 3 (15.8) 2 (13.3) 2 (25)
Positive 19 (82.6) 3 (75) 16 (84.2) 13 (86.7) 6 (75)
n/a 7 1 6 3 4
Surgery, n (%) 0.54 0.02
Yes 26 (86.7) 4 (80) 22 (88) 18 (100) 8 (66.7)
No 4 (13.3) 1 (20) 3 (12) 0 (0) 4 (33.3)
Unknown 0 0 0
IMRT, n (%) 0.34 0.72
Yes 13 (44.8) 1 (20) 12 (50) 7 (41.2) 6 (50)
No 16 (55.2) 4 (80) 12 (50) 10 (58.8) 6 (50)
Unknown 1 0 1 1 0
Chemotherapy, n (%) 0.33 0.71
Yes 14 (48.3) 1 (20) 13 (54.2) 9 (52.9) 5 (41.7)
No 15 (51.7) 4 (80) 11 (45.8) 8 (47.1) 7 (58.3)
Unknown 1 0 1 1
Boldface indicates that p < 0.05 is statistically significant.
ab-hCG–positive vs. negative.
bPAX8-positive vs. negative.
n/a, not available; SD, standard deviation; IMRT, intensity modulated radiation therapy.
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Table 2. Immunohistochemical Staining Patterns for b-hCG and PAX8 with Corresponding Survival Data
b-hCG
Case Distribution Intensity PAX8 Overall survival (days) Status at last follow-up
1 + + + + Strong Negative 887a Alive
2 + + Moderate Positive 137 Dead
3 + + + Moderate Negative 14 Dead
4 + Strong Negative 106 Dead
5 + Moderate Positive 57 Dead
6 Negative Positive 231 Dead
7 Negative Positive 88 Dead
8 Negative Positive 53 Dead
9 Negative Positive 226 Dead
10 Negative Positive No datab Unknown
11 Negative Positive 161 Dead
12 Negative Positive 43 Dead
13 Negative Positive 99 Dead
14 Negative Positive 121 Dead
15 Negative Positive 653 Dead
16 Negative Positive 3210 Alive
17 Negative Positive 90 Dead
18 Negative Positive 1521 Dead
19 Negative Positive 300 Dead
20 Negative Positive 146 Dead
21 Negative Positive 715 Dead
22 Negative Negative 218 Dead
23 Negative Negative 71 Dead
24 Negative Negative 164 Dead
25 Negative Negative 60 Dead
26 Negative Negative 19 Dead
27 Negative Negative 59 Dead
28 Negative Negative 55 Dead
29 Negative Negative 92 Dead
30 Negative Negative 58 Dead
aSentinel case; patient alive and without evidence of disease.
bNo follow-up data obtainable; patient lost to follow-up.
+, positive staining (in quartiles).
FIG. 4. Representative
PAX8-positive and b-hCG–
positive anaplastic carci-
noma cases from the addi-
tional cohort. (A) PAX8-
positive tumor showing
diffuse, strong nuclear
staining in most of the tu-
mor cells (400· ). (B) b-
hCG–positive tumor show-
ing strong staining in less
than 25% of tumor cells
(200 · ). Color images
available online at www
.liebertpub.com/thy
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Radiation, with or without chemotherapy, also improves lo-
coregional disease control and survival (7,8). However, it is
distinctly uncommon for patients to be cured of their disease.
Despite the emergence of small molecule inhibitors and
monoclonal antibodies in modern cancer care, there are still
no targeted therapies proven to be effective for ATC.
Our study is the first to report a b-hCG–secreting ATC and,
further, is the first to characterize a cohort of ATC for im-
munohistochemical expression of b-hCG. This tumor, unlike
typical ATC, was highly treatment-responsive and has had a
favorable outcome at two and a half years of follow-up. The
anaplastic carcinoma component, although surgically un-
resectable at presentation, responded dramatically to intensity
modulated radiation therapy and taxotere chemotherapy. It
became surgically resectable and since that time, the patient
has been alive and free of ATC, although she did have a nodal
recurrence of Hu¨rthle cell carcinoma 18 months after surgery,
which was treated effectively. The tumor secreted b-hCG de-
tectable in the serum, which persisted after chemoradiation
but became nondetectable after the first surgical procedure.
This confirms that the source of the b-hCG in the serum was
theATC. Quantitative serum b-hCG levels have been obtained
every 6 months, which have continued to be undetectable.
In the follow-up study of 29 more ATC cases, the four ad-
ditional b-hCG–positive patients all rapidly died of disease
despite three undergoing surgical resection. However, none
of them was subsequently treated with either chemotherapy
or radiation. Although it is difficult to draw conclusions from
one case, strongly b-hCG–positive ATC, particularly as
manifested by positive serum b-hCG levels, may be a unique
entity with a favorable outcome. The diagnosis of primary
thyroid choriocarcinoma was strongly considered and ruled
out for several reasons: (i) themorphology lacked the biphasic
cyto- and syncytiotrophoblastic cells seen with choriocarci-
noma; (ii) there was a differentiated thyroid carcinoma com-
ponent intimately associated with the undifferentiated
carcinoma; (iii) the tumor lacked expression of inhibin, a very
sensitive marker of trophoblastic differentiation, and also
lacked expression of placental alkaline phosphatase; (iv) a
choriocarcinoma would have manifested much higher serum
b-hCG levels, especially relative to the large size of the thyroid
mass; and, finally, (v) no primary thyroid choriocarcinoma
has ever been described.
PAX8 immunohistochemistry was also performed, and 18
of the 30 cases showed staining in the ATC component of the
tumors. This is comparable to the emerging literature on this
marker in thyroid cancer (19,20) and again shows that PAX8,
which appears to be quite specific for thyroid follicular dif-
ferentiation, at least among head and neck tumors, is a good
marker for ATC in cases where the diagnosis may not be
straightforward. PAX8 is much more consistently expressed
in ATC than thyroglobulin and thyroid transcription factor 1,
the other markers of follicular differentiation, which are only
expressed in less than 25% of cases (19,22). Interestingly, the
expression of b-hCG and PAX8 does not appear to be related.
Only 2 of the 5 b-hCG–positive cases were positive for PAX8,
and the index case with diffuse b-hCG expression and known
elevated serum levels was negative, despite coming from a
background of Hu¨rthle cell carcinoma. Ours is the first study
to find PAX8 expression to be prognostic. The patients with
PAX8-positive ATC had statistically significantly better
overall survival in univariate analysis. This is tempered by the
fact that PAX8-positive tumors were more frequent in youn-
ger patients and in patients undergoing surgical treatment,
both ofwhichwere also associatedwith improved survival. In
particular, patients with ATC who have been candidates for
surgical resection and multimodality therapy have been
shown to have improved survival.
FIG. 5. Univariate overall
survival curves for b-hCG and
PAX8 expression, patient age,
and surgical treatment.
b-HCG AND PAX8 IN ANAPLASTIC THYROID CARCINOMA 325
What is the significance of b-hCG in ATC? This index case
suggests that b-hCG–secreting ATC may be a unique entity
and that it may be associated with more treatment-responsive
disease. However, it is just a single case. Since patients with
ATC are not routinely tested for b-hCG, either by serum or
urine testing or by tumor immunohistochemistry, the fre-
quency of this association is unknown. Since hCG has been
shown to be expressed (and sometimes secreted in the circu-
lation) by nontrophoblastic carcinomas at various sites [most
notably the urinary bladder (10) and lung (16)], the current
case may just be a rare example of this phenomenon in ATC.
Interestingly, b-hCG production has been associated in some
studies with more aggressive clinical behavior (16), which was
definitely not the finding in our case. Further studies and ob-
servation for additional cases of ATC that express b-hCG will
be critical for ascertaining both the frequency of this association
and if it truly bears reproducible clinical significance.
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